Clinical Trial Update: Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)

View source ↗

Summary

A completed cost-effectiveness study evaluating the miRview Mets diagnostic test in patients with cancer of unknown primary.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Unknown Primary

Drugs mentioned

• miRview Mets

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Neoplasms, Unknown Primary | Status: COMPLETED